View More Recent Stories
-
Sarepta Therapeutics (SRPT) PT Raised to $213 at BofA Securities
-
Goldman Sachs Reiterates Buy Rating on Sarepta Therapeutics (SRPT)
-
Sarepta Therapeutics (SRPT) PT Raised to $182 at RBC Capital
-
Sarepta Therapeutics (SRPT) to resume trading at 5:35PM
-
Sarepta Therapeutics (SRPT) Announces Expanded FDA Approval of ELEVIDYS
-
Sarepta Therapeutics (SRPT) Receives FDA Approval of Delandistrogene in DMD
-
Sarepta Therapeutics (SRPT) halted, news pending
-
RBC Capital Reiterates Outperform Rating on Regenxbio Inc. (RGNX)
-
BMO Capital Reiterates Outperform Rating on Sarepta Therapeutics (SRPT)
-
Sarepta Therapeutics gains as Pfizer failure removes overhang
-
BMO Capital Reiterates Outperform Rating on Sarepta Therapeutics (SRPT)
-
Piper Sandler Reiterates Overweight Rating on Sarepta Therapeutics (SRPT)
-
After-hours movers: Broadcom, Dave & Buster's, Oxford Industries, and more
-
Sarepta Therapeutics (SRPT) Climbs After Pfizer (PFE) Study in DMD Fails
